In agreement with these observations, our data suggest that VEGF is the major determinant of tumour growth but certainly do not rule out the possibility that other factors may also be involved in determining the sensitivity of the tumours to a VEGFR2 inhibitor. The gene discussed is VEGFA; the disease is neoplasm.